Inovio opens phase II segment of phase II/III study evaluating COVID-19 vaccine candidate INO-4800 Nov. 17, 2020
Phase III study of mRNA-1273 for COVID-19 meets primary efficacy endpoint at interim analysis Nov. 16, 2020
RSS